Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bladder cancer combo therapy trial cut short – what we know

NCT ID NCT03324282

Terminated Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested whether adding the immunotherapy avelumab to standard chemotherapy (gemcitabine-cisplatin) helps people with advanced bladder cancer that has spread. The study planned to enroll 65 patients but was terminated early. Researchers measured tumor shrinkage and side effects. Because it stopped early, the results are not conclusive, but the data may still offer clues about combining immunotherapy with chemo for this cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
avelumab (immunotherapy) plus gemcitabine-cisplatin (chemotherapy)
What this could lead to
If successful, this combination could improve response rates and delay disease progression for people with advanced bladder cancer.
What could go wrong
The trial was terminated early with only 65 participants, so results are limited. Immunotherapy can cause immune-related side effects, and the added benefit over chemo alone is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CARCINOMA

Contacts and locations

Locations

  • CHU de Besançon

    Besançon, France

  • CHU de Bordeaux

    Bordeaux, France

  • CHU de Poitiers

    Poitiers, France

  • CHU de Strasbourg

    Strasbourg, France

  • Centre François Baclesse

    Caen, France

  • Centre Léon Bérard

    Lyon, France

  • Hôpital Européen Georges-Pompidou, AP-HP

    Paris, France

  • Hôpital Saint-Louis, AP-HP

    Paris, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Gustave Roussy

    Villejuif, France

  • Institut Paoli Calmettes

    Marseille, France

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, France

  • Institut de cancérologie de l'Ouest - René Gauducheau

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.